With this method, we identified Lenvatinib as a promising clinical agent against AM, and, based on available clinical evidence, encourage clinician to consider using this, or a regionally available dual FGFR/VEGFR inhibitor, for the treatment of acral melanoma. This evidence concerns the gene KDR and acral lentiginous melanoma.